praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res
Company profile
Ticker
PRAX
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
PRAX stock data
Latest filings (excl ownership)
8-K
Other Events
29 Mar 24
424B5
Prospectus supplement for primary offering
29 Mar 24
424B5
Prospectus supplement for primary offering
27 Mar 24
8-K
Other Events
26 Mar 24
EFFECT
Notice of effectiveness
13 Mar 24
S-3
Shelf registration
5 Mar 24
S-8
Registration of securities for employees
5 Mar 24
8-K
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
5 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
S-8
Registration of securities for employees
31 Jan 24
Latest ownership filings
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
4
Lauren Mastrocola
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
4
Alex Nemiroff
14 Feb 24
4
Marcio Souza
14 Feb 24
SC 13G/A
PFM Health Sciences, LP
14 Feb 24
SC 13G/A
Cormorant Asset Management, LP
14 Feb 24
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 24
SC 13G/A
Tri Locum Partners LP
14 Feb 24
SC 13G
Verition Fund Management LLC
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 101.50 mm | 101.50 mm | 101.50 mm | 101.50 mm | 101.50 mm | 101.50 mm |
Cash burn (monthly) | 7.74 mm | (no burn) | 8.51 mm | 11.67 mm | 7.74 mm | 9.67 mm |
Cash used (since last report) | 51.56 mm | n/a | 56.67 mm | 77.74 mm | 51.56 mm | 64.45 mm |
Cash remaining | 49.94 mm | n/a | 44.83 mm | 23.76 mm | 49.94 mm | 37.05 mm |
Runway (months of cash) | 6.5 | n/a | 5.3 | 2.0 | 6.5 | 3.8 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 80 |
Opened positions | 25 |
Closed positions | 33 |
Increased positions | 18 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 131.24 bn |
Total shares | 147.78 mm |
Total puts | 0.00 |
Total calls | 30.30 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Venrock Healthcare Capital Partners III | 12.35 mm | $13.59 mm |
Point72 Asset Management | 10.55 mm | $12.13 bn |
Verition Fund Management | 10.49 mm | $12.06 bn |
Cormorant Asset Management | 9.50 mm | $10.93 bn |
Cormorant Global Healthcare Master Fund | 9.50 mm | $10.45 mm |
Partner Fund Management | 8.89 mm | $10.23 bn |
Sphera Funds Management | 8.76 mm | $10.08 bn |
Adage Capital Partners GP, L.L.C. | 7.93 mm | $9.12 bn |
VR Adviser | 5.30 mm | $6.10 bn |
Kingdon Capital Management, L.L.C. | 5.20 mm | $5.98 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Jan 24 | Lauren Mastrocola | Stock Option Common Stock | Grant | Acquire A | No | No | 43.37 | 12,000 | 520.44 k | 12,000 |
12 Jan 24 | Alex Nemiroff | Stock Option Common Stock | Grant | Acquire A | No | No | 43.37 | 30,000 | 1.30 mm | 30,000 |
12 Jan 24 | Marcio Souza | Stock Option Common Stock | Grant | Acquire A | No | No | 43.37 | 100,000 | 4.34 mm | 100,000 |
12 Jan 24 | Timothy Edwin Kelly | Stock Option Common Stock | Grant | Acquire A | No | No | 43.37 | 30,000 | 1.30 mm | 30,000 |
7 Jan 24 | Lauren Mastrocola | Common Stock | Payment of exercise | Dispose F | No | No | 25.19 | 35 | 881.65 | 1,975 |
News
Praxis Precision Medicines Priced $200M Offering of 3.3M Shares at $56.50/Share
28 Mar 24
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
26 Mar 24
Jefferies Maintains Buy on Praxis Precision Medicine, Raises Price Target to $128
26 Mar 24
Why Praxis Precision Medicines Stock Is Trading Higher Tuesday
26 Mar 24
HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $105 Price Target
26 Mar 24
Press releases
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
12 Apr 24
Praxis Precision Medicines to Participate in Upcoming April Conferences
5 Apr 24
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 Apr 24
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
28 Mar 24
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
27 Mar 24